|  | rESWTa (n = 13) | LCsIb (n = 12) | ||
---|---|---|---|---|---|
Outcome variable | Follow-up sessions | Mean +/− SD | p value | Mean +/− SD | p value |
Visual analogue scale | Baseline | 2.4 +/−  2.5 |  | 2.6 +/−  2.0 |  |
Week 1 | 1.3 +/−  2.0 | 0.18 | 1.6 +/−  1.7 | 0.08 | |
Week 4 | 1.3 +/−  1.9 | 0.15 | 1.4 +/−  1.5 | 0.08 | |
Week 12 | 0.65 +/− 1.2 | 0.022* | 1.9 +/− 2.7 | 0.52 | |
Week 24 | 0.35 +/− 0.81c | 0.0075* | 1.7 +/− 2.1 | 0.19 | |
Symptom severity score | Baseline | 21 +/− 6.4 |  | 22 +/− 5.1 |  |
Week 1 | 19 +/− 7.4 | 0.33 | 17 +/− 4.5 | 0.0047* | |
Week 4 | 17 +/−  4.3 | 0.031* | 17 +/−  5.1 | 0.011* | |
Week 12 | 15 +/− 4.5 | 0.0082* | 18 +/− 5.5 | 0.13 | |
Week 24 | 13 +/− 2.9c | 0.0059* | 19 +/− 7.9 | 0.20 | |
Functional score | Baseline | 14 +/− 3.2 |  | 12 +/− 4.1 |  |
Week 1 | 13 +/− 4.2 | 0.27 | 11 +/− 3.2 | 0.31 | |
Week 4 | 13 +/−  3.5 | 0.12 | 11 +/−  3.3 | 0.39 | |
Week 12 | 11 +/− 3.0 | 0.0065* | 10 +/− 3.4 | 0.19 | |
Week 24 | 11 +/− 2.2c | 0.0073* | 13 +/− 7.0 | 0.65 | |
Boston questionnaire score | Baseline | 35 +/− 8.5 |  | 34 +/− 8.5 |  |
Week 1 | 32 +/− 10 | 0.28 | 28 +/− 7.0 | 0.037* | |
Week 4 | 30 +/− 7.1 | 0.032* | 28 +/− 8.0 | 0.05 | |
Week 12 | 26 +/− 6.8 | 0.0040* | 29 +/− 8.2 | 0.13 | |
Week 24 | 24 +/− 4.7c | 0.0037* | 32 +/− 14 | 0.47 | |
Peak sensory distal latency | Baseline | 4.5 +/− 0.72 |  | 3.7 +/− 1.3 |  |
Week 12 | 4.1 +/− 0.74d | 0.0047* | 3.6 +/− 1.3 | 0.026* | |
SNAPe amplitude | Baseline | 17 +/− 6.9 |  | 18 +/− 11 |  |
Week 12 | 18 +/− 6.5d | 0.66 | 21 +/− 12 | 0.28 | |
Motor distal latency | Baseline | 4.5 +/− 0.35 |  | 4.7 +/−  0.90 |  |
Week 12 | 4.2 +/− 0.42d | 0.084 | 4.4 +/− 0.75 | 0.06 | |
CMAPf amplitude | Baseline | 6.9 +/− 1.5 |  | 6.0 +/− 0.61 |  |
Week 12 | 6.9 +/− 1.6d | 0.91 | 6.5 +/− 1.2 | 0.20 |